Key result
Mass distribution of a single dose of azithromycin for trachoma prevention was previously shown to reduce all-cause mortality by 49% among Ethiopian children, prompting further multinational trials.
Answers are grounded in this paper and cite their sources.
Editorial discussing the rationale for trials investigating mass azithromycin distribution for mortality reduction in children in trachoma-endemic areas.
In 2009, a cluster-randomized trial showed a 49% reduction in all-cause mortality among Ethiopian children 1 to 9 years of age in the year after mass distribution of a single dose of azithromycin for trachoma prevention — a reduction that was sustained over the following 26 months.1 This remarkable finding led to further multinational cluster-randomized trials examining mass distribution of azithromycin for children 1 to 59 months of age in trachoma-endemic areas of Niger, Tanzania, and Malawi (the Macrolides Oraux pour Réduire les Décès avec un Oeil sur la Résistance [MORDOR] trial)2 and such distribution combined with seasonal malaria prophylaxis . . .
No takes yet. Share an insight, caveat, or question.
Maitland et al. (2024) conducted an editorial in Trachoma prevention. Azithromycin was evaluated on all-cause mortality (49% reduction). Mass distribution of a single dose of azithromycin for trachoma prevention was previously shown to reduce all-cause mortality by 49% among Ethiopian children, prompting further multinational trials.
Synapse has enriched 10 related papers. Consider them for comparative context: